NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options
Summary
Finnish biotech company NADMED has developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fresh blood in hours, with the highest accuracy on the market. NADMED provides crucial information on vitamin B3 deficiencies, which have been linked to degenerative age-related diseases such as metabolic diseases, cancer, neurodegenerative and heart diseases.HELSINKI, Finland (August 22nd, 2024) Finnish biotech company has closed a 3.5M series A round to fund its entry into the U.S. and other international markets with its proprietary nicotinamide adenine dinucleotide (NAD) measurement technology that may help clinicians establish more precise and personalized treatments for various diseases.The round was led by Finnish science-based startup investor . NAD measurement should also be considered for unexplained fatigue, muscle weakness, long Covid, or unexpected drug side effects.Based on years of research from Professor Anu Suomalainen Wartiovaaras laboratory at the University of Helsinki, NADMEDs testing method is the first on the market to measure all four NADs using fresh blood samples quickly and efficiently with the same accuracy as mass spectrometry. This investment will enable us to bring new capabilities to diagnostics, therapy monitoring, personalized medicine, and advancement of metabolic science for the benefit of mankind.Accurate NAD and glutathione testing methods can lead to improved diagnosis, treatment, and monitoring of these conditions, making significant advancements in biotechnology and medical research and ultimately enhancing global health outcomes.NAD levels can easily be elevated with B3 vitamin supplementation, which has already shown promising outcomes in conditions such as Parkinsons disease, glaucoma, and mitochondrial myopathy. For investors, the companys diverse target market not only provides robust risk mitigation but also presents exciting growth opportunities across multiple sectors, said Alexandra Gylfe, Founding Partner at NSI.
Funding
Review available funding amount, funding date, investors, and linked company information related to NADMED raises €3.5M to bring NAD tests to international markets, advancing personalized treatment options in the interactive ISVWorld profile.